G C Timmis - JoVE Visualize

Showing results (51-60 of 59) with videos related to

Pageof 6

Sort By:

You have reached the last page of results.This site can display upto 59 results.

Annals of Internal Medicine|August 1, 1991

Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapyD R Cragg, H Z Friedman, J D Bonema, et al.

Circulation|November 1, 1992

Randomized trial of thrombolysis versus heparin in unstable anginaT L Schreiber, D Rizik, C White, et al.

Journal of the American College of Cardiology|February 11, 1999

A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical EvaluationM A Stevens, P A McCullough, K J Tobin, et al.

Pacing and Clinical Electrophysiology : PACE|November 1, 1986

Twelve years of clinical experience with lithium pulse generatorsR G Hauser, E A Wimer, G C Timmis, et al.

Journal of the American College of Cardiology|May 1, 1996

Prospective, randomized trial of prolonged intracoronary urokinase infusion for chronic total occlusions in native coronary arteriesF J Zidar, B M Kaplan, W W O'Neill, et al.

The American Journal of Cardiology|July 22, 1998

Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor BlockadeS Ghaffari, D J Kereiakes, A M Lincoff, et al.

The New England Journal of Medicine|May 4, 2000

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic EventsW W O'Neill, P Serruys, M Knudtson, et al.

Circulation|April 20, 1999

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockadeA M Lincoff, J E Tcheng, R M Califf, et al.

Journal of the American College of Cardiology|June 17, 1998

Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisJ S Mandak, J C Blankenship, L H Gardner, et al.

Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:

Pageof 6

You have reached the last page of results.This site can display upto 59 results.

Annals of Internal Medicine|August 1, 1991

Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapyD R Cragg, H Z Friedman, J D Bonema, et al.

Circulation|November 1, 1992

Randomized trial of thrombolysis versus heparin in unstable anginaT L Schreiber, D Rizik, C White, et al.

Journal of the American College of Cardiology|February 11, 1999

A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical EvaluationM A Stevens, P A McCullough, K J Tobin, et al.

Pacing and Clinical Electrophysiology : PACE|November 1, 1986

Twelve years of clinical experience with lithium pulse generatorsR G Hauser, E A Wimer, G C Timmis, et al.

Journal of the American College of Cardiology|May 1, 1996

Prospective, randomized trial of prolonged intracoronary urokinase infusion for chronic total occlusions in native coronary arteriesF J Zidar, B M Kaplan, W W O'Neill, et al.

The American Journal of Cardiology|July 22, 1998

Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor BlockadeS Ghaffari, D J Kereiakes, A M Lincoff, et al.

The New England Journal of Medicine|May 4, 2000

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic EventsW W O'Neill, P Serruys, M Knudtson, et al.

Circulation|April 20, 1999

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockadeA M Lincoff, J E Tcheng, R M Califf, et al.

Journal of the American College of Cardiology|June 17, 1998

Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisJ S Mandak, J C Blankenship, L H Gardner, et al.

Pageof 6